Skip to main content
KYONGBO PHARMACEUTICAL CO., LTD. logo

KYONGBO PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 214390 ISIN · KR7214390007 LEI · 988400YKOM1CHDS6R917 KO Manufacturing
Open in API
Filings indexed 206 across all filing types
Latest filing 2023-08-11 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 214390

About KYONGBO PHARMACEUTICAL CO., LTD.

https://www.kbpharma.co.kr/en/home

Kyongbo Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished drug products. The company also operates as a Contract Development and Manufacturing Organization (CDMO), offering integrated services from early-stage development through to commercial cGMP production. Its core product portfolio includes a diverse range of APIs, such as sterile and non-sterile cephalosporins, carbapenem antibiotics, and high-potency cytotoxic anti-cancer agents. In addition to APIs, the company manufactures finished dosage forms, including solid oral medications and sterile injectables. Kyongbo Pharmaceutical utilizes dedicated and segregated manufacturing facilities to produce its specialized product lines, supported by a strong commitment to research and innovation in API synthesis.

Recent filings

Filing Released Lang Actions
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'Kyongbo Pharmaceutical' (주)경보제약, covering the period from January 1, 2023, to June 30, 2023. It contains detailed financial data, business operations, and management information. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (like a half-year report) containing actual financial statements and analysis is classified as an Interim / Quarterly Report (IR). H1 2023
2023-08-11 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Kyongbo Pharmaceutical for the second quarter of 2023. It provides key financial highlights such as revenue, operating profit, and net income in a summary table format. It is clearly an initial announcement of financial results rather than a full quarterly report or a report publication announcement, fitting the definition of an Earnings Release (ER). H1 2023
2023-07-28 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Kyongbo Pharmaceutical' (주식회사 경보제약) covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial information, business operations, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Kyongbo Pharmaceutical for the first quarter of 2023. It provides key financial highlights such as revenue, operating profit, and net income in a table format. This fits the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results. Q1 2023
2023-04-28 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory disclosure for insider shareholdings, which falls under the 'Director's Dealing' category as it reports the acquisition of shares by a newly appointed executive (Chae Hyeon-Suk).
2023-03-24 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) filed by Kyongbo Pharmaceutical. It details specific changes in share ownership by individuals classified as major shareholders or executives (such as the appointment of a new executive, Chae Hyun-sook). This type of filing is a standard regulatory requirement in South Korea for reporting changes in the holdings of major shareholders and insiders, which aligns with the 'Major Shareholding Notification' (MRQ) category.
2023-03-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.